These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 28137841)

  • 1. Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis.
    Andrews FH; Singh AR; Joshi S; Smith CA; Morales GA; Garlich JR; Durden DL; Kutateladze TG
    Proc Natl Acad Sci U S A; 2017 Feb; 114(7):E1072-E1080. PubMed ID: 28137841
    [No Abstract]   [Full Text] [Related]  

  • 2. Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4- and MYC-dependent manner.
    Mishra VK; Wegwitz F; Kosinsky RL; Sen M; Baumgartner R; Wulff T; Siveke JT; Schildhaus HU; Najafova Z; Kari V; Kohlhof H; Hessmann E; Johnsen SA
    Nucleic Acids Res; 2017 Jun; 45(11):6334-6349. PubMed ID: 28369619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer.
    Joshi S; Singh AR; Liu KX; Pham TV; Zulcic M; Skola D; Chun HB; Glass CK; Morales GA; Garlich JR; Durden DL
    Mol Cancer Ther; 2019 Jun; 18(6):1036-1044. PubMed ID: 31018997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JQ1 and PI3K inhibition synergistically reduce salivary adenoid cystic carcinoma malignancy by targeting the c-Myc and EGFR signaling pathways.
    Liu X; Wu H; Huang P; Zhang F
    J Oral Pathol Med; 2019 Jan; 48(1):43-51. PubMed ID: 30269363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual PI3K-BRD4 Inhibitor SF1126 Inhibits Colorectal Cancer Cell Growth in Vitro and in Vivo.
    Qin AC; Li Y; Zhou LN; Xing CG; Lu XS
    Cell Physiol Biochem; 2019; 52(4):758-768. PubMed ID: 30933440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR-mediated signaling pathway influences the sensitivity of oral squamous cell carcinoma to JQ1.
    Liu X; Li Q; Huang P; Tong D; Wu H; Zhang F
    J Cell Biochem; 2018 Oct; 119(10):8368-8377. PubMed ID: 30687956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.
    Rhyasen GW; Hattersley MM; Yao Y; Dulak A; Wang W; Petteruti P; Dale IL; Boiko S; Cheung T; Zhang J; Wen S; Castriotta L; Lawson D; Collins M; Bao L; Ahdesmaki MJ; Walker G; O'Connor G; Yeh TC; Rabow AA; Dry JR; Reimer C; Lyne P; Mills GB; Fawell SE; Waring MJ; Zinda M; Clark E; Chen H
    Mol Cancer Ther; 2016 Nov; 15(11):2563-2574. PubMed ID: 27573426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SF2523 inhibits human chondrosarcoma cell growth in vitro and in vivo.
    Zhu JX; Xiao JR
    Biochem Biophys Res Commun; 2019 Apr; 511(3):559-565. PubMed ID: 30824188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CUDC-907 displays potent antitumor activity against human pancreatic adenocarcinoma in vitro and in vivo through inhibition of HDAC6 to downregulate c-Myc expression.
    Fu XH; Zhang X; Yang H; Xu XW; Hu ZL; Yan J; Zheng XL; Wei RR; Zhang ZQ; Tang SR; Geng MY; Huang X
    Acta Pharmacol Sin; 2019 May; 40(5):677-688. PubMed ID: 30224636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual inhibition of BRD4 and PI3K by SF2523 suppresses human prostate cancer cell growth in vitro and in vivo.
    Shen G; Jiang M; Pu J
    Biochem Biophys Res Commun; 2018 Jan; 495(1):567-573. PubMed ID: 29133261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JQ1, an inhibitor of the epigenetic reader BRD4, suppresses the bidirectional MYC-AP4 axis via multiple mechanisms.
    Choi SK; Hong SH; Kim HS; Shin CY; Nam SW; Choi WS; Han JW; You JS
    Oncol Rep; 2016 Feb; 35(2):1186-94. PubMed ID: 26573731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
    Hu J; Wang Y; Li Y; Xu L; Cao D; Song S; Damaneh MS; Wang X; Meng T; Chen YL; Shen J; Miao Z; Xiong B
    Eur J Med Chem; 2017 Sep; 137():176-195. PubMed ID: 28586718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
    Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
    Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers.
    Bihani T; Ezell SA; Ladd B; Grosskurth SE; Mazzola AM; Pietras M; Reimer C; Zinda M; Fawell S; D'Cruz CM
    Oncotarget; 2015 Feb; 6(4):2407-20. PubMed ID: 25537515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma.
    Felgenhauer J; Tomino L; Selich-Anderson J; Bopp E; Shah N
    Neoplasia; 2018 Oct; 20(10):965-974. PubMed ID: 30153557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy.
    Stratikopoulos EE; Dendy M; Szabolcs M; Khaykin AJ; Lefebvre C; Zhou MM; Parsons R
    Cancer Cell; 2015 Jun; 27(6):837-51. PubMed ID: 26058079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reciprocal control of Forkhead box O 3a and c-Myc via the phosphatidylinositol 3-kinase pathway coordinately regulates p27Kip1 levels.
    Chandramohan V; Jeay S; Pianetti S; Sonenshein GE
    J Immunol; 2004 May; 172(9):5522-7. PubMed ID: 15100294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734.
    Morrison-Smith CD; Knox TM; Filic I; Soroko KM; Eschle BK; Wilkens MK; Gokhale PC; Giles F; Griffin A; Brown B; Shapiro GI; Zucconi BE; Cole PA; Lemieux ME; French CA
    Mol Cancer Ther; 2020 Jul; 19(7):1406-1414. PubMed ID: 32371576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells.
    Ischenko I; Petrenko O; Hayman MJ
    Oncotarget; 2015 Jun; 6(18):15814-27. PubMed ID: 26158412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Augmented Antitumor Activity for Novel Dual PI3K/BDR4 Inhibitors, SF2523 and SF1126 in Ewing Sarcoma.
    Goldin AN; Singh A; Joshi S; Jamieson C; Durden DL
    J Pediatr Hematol Oncol; 2021 Apr; 43(3):e304-e311. PubMed ID: 33480647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.